Herantis Pharma Oyj
HRPMF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $68,338 | $65,939 | $55,501 | $54,404 |
| - Cash | $635 | $1,989 | $5,503 | $3,926 |
| + Debt | $30 | $30 | $35 | $4,541 |
| Enterprise Value | $67,733 | $63,980 | $50,033 | $55,019 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,252 | -$5,361 | $1,317 | -$563 |
| % Margin | – | – | – | – |
| Net Income | -$2,253 | -$2,687 | $1,037 | -$897 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.11 | -0.13 | 0.059 | -0.053 |
| % Growth | 15.4% | -318.9% | 211.9% | – |
| Operating Cash Flow | -$3,510 | -$3,035 | -$1,460 | -$859 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,510 | -$3,035 | -$1,460 | -$859 |